血管结构模式与肾细胞癌预后关系的研究进展

Research progress on the relationship between vascular structure patterns and prognosis of renal cell carcinoma

摘要

血管结构模式即血管的成熟度、形态及分布状态，其作为肾细胞癌病理特征之一，在肾细胞癌预后评估中的价值不容忽视。目前肾细胞癌血管结构模式常被分为假腺泡样、高尔基体样、腔隙样和分散样4种，与疾病诊断密切相关，早期特征如树枝状穿透内皮有助于肾细胞癌的鉴别诊断，不同的血管结构模式还与肿瘤分级相关，而且影响肿瘤对靶向治疗的反应性及患者预后。通过评估血管结构模式，可以帮助理解肿瘤的生物学行为并指导治疗方法选择。目前尚缺乏统一的血管结构模式的评估方式。本文对血管结构模式与肾细胞癌预后关系的研究进展进行综述，旨在为临床提供参考。

Abstract

Vascular structure pattern, namely the maturity, morphology and distribution of blood vessels, as one of the pathological features of renal cell carcinoma (RCC), cannot be ignored when the prognosis is concerned. The current mainstream classification of vascular structure patterns includes pseudoacini, Golgi, lacunar and dispersion patterns. Many studies have shown that the vascular structure patterns in RCC are closely related to the diagnosis and prognosis. Early features such as dendritic penetration of the endothelium contribute to the differential diagnosis of RCC, while different vascular structure patterns are not only related to tumor grade, but also affect the responsiveness of targeted therapy and prognosis. Evaluating these vascular structural patterns can help to understand the biological behaviors of tumors and guide the treatment options, but a unified assessment of vascular structural patterns is still lacking. This paper reviews the research progress on the relationship between vascular structure patterns and RCC prognosis, aiming to provide clinical reference.

关键词

肾细胞癌 / 血管结构 / 血管成熟度 / 肿瘤分级 / 预后

Key words

renal cell carcinoma / vascular structure / vascular maturity / tumor grade / prognosis

参考文献

[1] RINI BL, CAMPBELL SC, ESCUDIER B. Renal cell carcinoma[J]. Lancet, 2009, 373(9669): 1119-1132.

[2] LIAO C, HU L, ZHANG Q. Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma[J]. Nat Rev Urol, [ 2024-5-2]. doi: 10.1038/s41585-024-00876-w.

[3] DELAHUNT B, SRIGLEY JR, JUDGE MJ, et al. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR)[J]. Histopathology, 2019, 74(3): 377-390.

[4] COTTA BH, CHOUEIRI TK, CIESLIK M, et al. Current landscape of genomic biomarkers in clear cell renal cell carcinoma[J]. Eur Urol, 2023, 84(2): 166-175.

[5] WANG J, ZHAO E, GENG B, et al. Downregulation of UBB potentiates SP1/VEGFA-dependent angiogenesis in clear cell renal cell carcinoma[J]. Oncogene, 2024, 43(18): 1386-1396.

[6] FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.

[7] DUDLEY AC, GRIFFIOEN AW. Pathological angiogenesis: mechanisms and therapeutic strategies[J]. Angiogenesis, 2023, 26(3): 313-347.

[8] VIALLARD C, LARRIVÉE B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J]. Angiogenesis, 2017, 20(4): 409-426.

[9] YANG F, LEE G, FAN Y. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism[J]. Angiogenesis, 2024, 27(3): 333-349.

[10] SIEMANN DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents[J]. Cancer Treat Rev, 2011, 37(1): 63-74.

[11] NAGY JA, CHANG SH, DVORAK AM, et al. Why are tumour blood vessels abnormal and why is it important to know[J]. Br J Cancer, 2009, 100(6): 865-869.

[12] WU Y, DU K, GUAN W, et al. A novel definition of microvessel density in renal cell carcinoma: angiogenesis plus vasculogenic mimicry[J]. Oncol Lett, 2020, 20(5): 192.

[13] FERICIAN O, CIMPEAN AM, CEAUSU AR, et al. Heterogeneous vascular patterns in renal cell carcinomas[J]. Pol J Pathol, 2016, 67(1): 46-53.

[14] RUIZ-SAURÍ A, GARCÍA-BUSTOS V, GRANERO E, et al. Distribution of vascular patterns in different subtypes of renal cell carcinoma. A morphometric study in two distinct types of blood vessels[J]. Pathol Oncol Res, 2018, 24(3): 515-524.

[15] CANETE-PORTILLO S, RODRIGUEZ PENA MDC, WANG D, et al. Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma[J]. Virchows Arch, 2021, 479(6): 1187-1196.

[16] LI Y, REUTER VE, MATOSO A, et al. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients[J]. Histopathology, 2018, 72(4): 588-600.

[17] DELAHUNT B, SIKA-PAOTONU D, BETHWAITE PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence[J]. Am J Surg Pathol, 2011, 35(8): 1134-1139.

[18] DELAHUNT B, CHEVILLE JC, MARTIGNONI G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters[J]. Am J Surg Pathol, 2013, 37(10): 1490-1504.

[19] WARREN AY, HARRISON D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies[J]. World J Urol, 2018, 36(12): 1913-1926.

[20] WILLIAMSON SR, TANEJA K, CHENG L. Renal cell carcinoma staging: pitfalls, challenges, and updates[J]. Histopathology, 2019, 74(1): 18-30.

[21] WEIR M, PITMAN MB. The vascular architecture of renal cell carcinoma in fine-needle aspiration biopsies. An aid in its distinction from hepatocellular carcinoma[J]. Cancer, 1997, 81(1): 45-50.

[22] SARDARINIA P, HENDRIKS J, FRIEDEL G, et al. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma[J]. Histopathology, 2007, 51(3): 354-361.

[23] OHE C, YOSHIDA T, AMIN MB, et al. Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes[J]. Mod Pathol, 2022, 35(6): 816-824.

[24] OUYANG AM, WEI ZL, SU XY, et al. Relative computed tomography (CT) enhancement value for the assessment of microvascular architecture in renal cell carcinoma[J]. Med Sci Monit, 2017, 31; 23: 3706-3714.

[25] LÓPEZ JI, ERRAMUZPE A, GUARCH R, et al. CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma[J]. APMIS, 2017, 125(2): 128-133.

[26] QIAN CN, HUANG D, WONDERGEM B, et al. Complexity of tumor vasculature in clear cell renal cell carcinoma[J]. Cancer, 2009, 115(10 Suppl): 2282-2289.

[27] BARATA PC, ORNSTEIN MC, GARCIA JA. The evolving treatment landscape of advanced renal cell carcinoma in patients progressing after VEGF inhibition[J]. J Kidney Cancer VHL, 2017, 4(2): 10-18.

[28] 张俊飞， 刘春， 开梓翔， 等. 程序性死亡分子-1抑制剂纳武利尤单抗治疗晚期肾癌的新进展[J]. 现代泌尿外科杂志， 2020， 25（3）： 280-284.

[29] PLIMACK ER, TANNIR N, LIN E, et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures[J]. Cancer, 2009, 115(9): 1859-1866.

[30] SMITH NR, BAKER D, FARREN M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy[J]. Clin Cancer Res, 2013, 19(24): 6943-6956.

[31] CASCONET T, HERYNK MH, XU L, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma[J]. J Clin Invest, 2011, 121(4): 1313-1328.

[32] CRAWFORD Y, KASMAN I, YU L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment[J]. Cancer Cell, 2009, 15(1): 21-34.